<DOC>
	<DOC>NCT00652782</DOC>
	<brief_summary>A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.</brief_summary>
	<brief_title>Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Rolofylline</mesh_term>
	<criteria>Be able to provide written informed consent, Be a male or female at least 18 years of age, Be hospitalized for fluid overload requiring IV diuretic therapy History of use of diuretic therapy for CHF (including this admission), Be admitted to the hospital within 36 hours of the mandatory dose of IV furosemide 40 mg at between 2000 and 2200 hour on Day 1 Have had a myocardial infarction within 30 days prior to Day 1 Be pregnant or breastfeeding Have received intravascular contrast material within the preceding 14 days; or have acute contrast nephropathy Have had implantation of an automated implanted cardiac defibrillator (AICD) or synchronization device within the preceding 7 days Currently require mechanical ventilation, ultrafiltration, or hemodialysis, Have symptomatic ventricular tachycardia Be admitted for heart transplant surgery or have had a heart transplant, Have any other concomitant lifethreatening disease, Have participated in a clinical trial of an investigational drug or device within 30 days before randomization Have a positive urine pregnancy test (for women of childbearing capacity) Have an allergy to soybean oil and/or eggs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>